Plain-English translation of NCT06947967 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a drug called given together with standard chemotherapy (called CHOP) in people who have just been diagnosed with a specific type of T-cell lymphoma called peripheral T-cell lymphoma with follicular helper phenotype. Half of the participants will receive the medication plus chemotherapy, and half will receive chemotherapy plus a placebo (a dummy pill with no active drug). The goal is to see if adding this treatment improves how well the chemotherapy works.
This type of T-cell lymphoma can be difficult to treat, and current chemotherapy alone may not work well enough for all patients. Researchers believe that this medication might help the chemotherapy work better and improve outcomes for people with this diagnosis.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or a placebo, both given together with standard chemotherapy infusions. You would attend regular clinic visits for treatment, blood tests, and scans to monitor how you're responding. The trial involves 224 people at multiple hospitals, and your participation would include the treatment period plus follow-up visits to track your long-term response and any side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China